Interview

Genomics
#Clinical trials #Genetics / genomics #Interview #Personalised medicine #Rare disease

Sitting down with… Dr Patrick Short, Sano Genetics

DDW’s Diana Spencer caught up with Dr Patrick Short, CEO and Co-Founder, Sano Genetics, about the challenges facing personalised medicine development and his own personal experience of genetic conditions. DS: You and your co-founders met at the University of Cambridge. Can you tell us about the founding of the company?… Read More

#Exclusive Content

Lungs
#Autoimmune disease #Clinical trial #GSK #Interview #Lung disease

GSK’s autoimmune efforts

DDW Editor Reece Armstrong speaks to Roger Levy, Global Medical Expert Immunology & Specialty Medicine at GSK about the company’s work into treating systemic sclerosis-associated interstitial lung disease and its recent BLISSc-ILD study evaluating its belimumab treatment.  RA: Can you give us an overview of the BLISSc-ILD study? RL:… Read More

#Exclusive Content

Drug discovery innovation
#AAV #Cell and gene therapy #Drug development #Drug discovery #Gene therapy #Genetics / genomics #Immunology / Virology & Vaccines #Interview #Life sciences #Market reporting #Precision medicine #RNA #RNA sequencing #Scandinavia #Sweden #Transcriptomics

Podcast: Innovation drivers and opportunities for drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovation drivers and opportunities for drug discovery”, which covers three articles written Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Optimising AAV capsid purification through improved analytics How… Read More

#News

Tumour microenvironment
#Cell and gene therapy #Cell therapy #Interview #Oncology #T cell receptor (TCR)

Unlocking T-cell receptor therapy for cancer

Keir Loiacono, CEO of BlueSphere Bio, discusses the goals of the company’s lead programme, the opportunities and potential of T-cell receptor (TCR) T cell therapies, and how to make oncology therapies tailored to individuals a reality. The goals of TCX-101 BlueSphere’s lead programme, TCX-101, includes two goals. The first is… Read More

#Cancer Research #Exclusive Content

Natural killer cells
#Cell therapy #Imperial College London #Interview #Natural killer cells #NK:IO #Oncology

Natural born killers: University spinout turns NK cell therapy into business

Imperial College spinout NK:IO was awarded a £1.6m ($2m) Innovate UK New Cancer Therapeutics grant in 2023 to develop a pioneering NK cell therapy. Diana Spencer catches up with Co-Founder Mike Romanos to find out more. DS: How can NK cell therapy tackle the limitations of cancer immunotherapy? MR: … Read More

#Cancer Research #Exclusive Content #Opinion #Start-up Zone

#Cancer research #Career #Chemical biology #Curve Therapeutics #Drug discovery #High throughput screening #Interview #Meet the Researcher #Next generation sequencing #Target identi

Meet the researcher: Ali Tavassoli

DDW’s Megan Thomas talks to Ali Tavassoli, Chief Scientific Officer of Curve Therapeutics and Professor of Chemical Biology at the University of Southampton, UK.  MT: Where do you work, and can you tell us what you’re working on at the moment?  AT: We spun Curve out of my academic… Read More

#Cancer Research #Exclusive Content

Vaccine
#Clinical trial #Immunology / Virology & Vaccines #Interview #University of Oxford #Vaccines

Vaccines and various response rates

DDW Editor Reece Armstrong speaks to Dr Katrina Pollock from the Oxford Vaccine Group at the University of Oxford. Dr Pollock is the Chief Investigator of the LEGACY03 clinical trial, a study aiming to investigate lymph nodes and vaccination responses across age groups. RA: Could you tell us about the… Read More

#Exclusive Content

#Immunotherapy #Interview #Oncology #RNA

The role of RNA in immunotherapies

Reece Armstrong speaks to Samuel Deutsch, Chief Scientific Officer of Nutcracker Therapeutics about the RNA landscape and how it can benefit the development of immunotherapies. RA: What role does RNA play in the development of effective immunotherapies? SD: The ability of RNA therapies to use the body’s own mechanisms to… Read More

#Cancer Research #Exclusive Content

#Cancer research #Career #Interview #Meet the Researcher #University of Oslo

Meet the researcher: Dr Henrik Jespersen

DDW’s Megan Thomas talks to Dr Henrik Jespersen, Head of Melanoma Oncology, at Oslo University Hospital. MT: Where do you work, and can you tell us what you’re working on at the moment?  HJ: I work as a clinical oncologist at Oslo University Hospital where I am head of… Read More

#Exclusive Content

Vaccine
#Immunology / Virology & Vaccines #Interview #Structural biology #Vaccines

How structural biology is informing vaccine design

Reece Armstrong speaks to Melanie Adams-Cioaba, Senior Director and General Manager of pharma (cryo-EM), Thermo Fisher Scientific about advances in vaccine design. RA: How can rational design approaches help advance vaccine development?     MA: Regarding vaccine development specifically, and the role my team plays in the development of… Read More

#Exclusive Content

#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Interview

Why more work is needed to fight antimicrobial resistance

Reece Armstrong speaks to Professor Janet Hemingway CBE about current efforts in tackling antimicrobial resistance. The threat of AMR has been well documented in recent years. Perhaps the most notable effort came from the 2014 report “The Review on Antimicrobial Resistance” which was chaired by Lord Jim O’Neill and… Read More

#Exclusive Content

#Absci #Antibodies #Artificial intelligence (AI) #Biologics #Generative AI #Interview

The next generation of AI

Reece Armstrong speaks to Sean McClain, Founder & CEO of Absci, about the rise of generative AI in life sciences. The company has a biologics pipeline with a focus on differentiated antibodies targeting a range of indications.  Last year, a lot of focus was placed on artificial intelligence… Read More

#Exclusive Content

#Animal models #Interview #Sitting Down With #The Jackson Laboratory #Vodcast

Watch the latest DDW vodcast

The latest DDW Sitting Down With sponsored vodcast is now available. It features Dr Adriano Flora, Director of Business Development at The Jackson Laboratory (JAX). In this vodcast, he discusses alternatives to non-human primates, the key benefits of this, and what impact will they have on the future of… Read More

#News

#Drug development #Drug discovery #Interview #Sitting Down With #The Jackson Laboratory #Vodcast

Vodcast: Dr Adriano Flora, The Jackson Laboratory

The latest sponsored DDW Sitting Down With vodcast features Dr Adriano Flora, Director of Business Development at The Jackson Laboratory (JAX). He discusses alternatives to non-human primates, the key benefits of this, and what impact will they have on the future of drug development. Moreover, he answers questions on… Read More

#Videos